Abbott has collaborated on multiple important scientific publications using real-world data from its FreeStyle Libre platform.
FreeStyle Libre data that Abbott has de-identified and anonymized to comply with Abbott’s privacy policies and data protection laws, is used for research to help advance scientific discoveries and create meaningful innovations for people with diabetes. These insights are shared at global scientific healthcare conferences, published in peer-reviewed journals, and used to improve clinical standards and care.
A selection of scientific manuscripts that have analyzed FreeStyle Libre user data are linked below:
2022
Journal: Diabetology & Metabolic Syndrome
Summary: This real-world data study analyzed glucose metrics from FreeStyle Libre in relation to scanning frequency, time in range (TIR) and estimated A1c (eA1c) in Saudi Arabia. Read More
The data set for Saudi Arabia included 6097 readers, 35,747 sensors, and 40 million automatic glucose measurements. Higher scanning frequency in flash glucose users from Saudi Arabia is associated with lower eA1c, higher TIR, lower glucose variability and less time in hypoglycemia or hyperglycemia.
Journal: Endocrine Practice
Summary: Flash glucose monitoring has been widely used in Israel for diabetes treatment and since 2018, the cost is reimbursed for all people with type 1 diabetes nationally. Read More
The data set included 12,370 readers, with data from 131,639 separate glucose sensors. In Israel, people with diabetes under real-world conditions recorded higher rates of FreeStyle Libre scanning. These higher scan rates were associated with improvements in time in range, estimated HbA1c, and reduced time with glucose levels of >180 mg/dL or <54 mg/dL.
2021
Journal: Diabetes Research and Clinical Practice
Details: Cited by multiple articles, including 2022 ADA Standards of Care
Summary: The aim of the study was to evaluate the use of FLASH under real-life circumstances in the Netherlands and to assess the effects on glycemic parameters. Read More
Data comprising 16,331 readers (163,762 sensors) were analyzed. Increasing scan rates were associated with more time in range, less time in hyperglycemia, and a lower standard deviation of glucose. These outcomes among Dutch FLASH users suggest that with higher scan rate glycemic control improves.
Journal: Diabetes Technology & Therapeutics
Summary: In this retrospective, real-world data analysis, country-specific glucometrics among isCGMS users from Poland were described and compared with international data. Read More
This analysis used 5,804 readers from Argentina and 950,234 readers worldwide. A strong association was observed between highest scanning frequency and better glucose metrics, including less time below 54 mg/dL, less time above 250 mg/dL, lower estimated HbA1c level, lower glucose coefficient of variability (CV) and longer time within the therapeutic target (70 to 180 mg/dL).
Journal: Journal of Diabetes Science and Technology
Summary: This retrospective analysis compared glucose metrics of FreeStyle Libre 14-day users in the United States (14,000 users of the FreeStyle LibreLink app and 14,000 users of the FreeStyle Libre 14-day reader). Read More
Data from the Polish population were collected from 10,679 readers and 92,627 sensors. The worldwide database included information from 981,876 readers and 11,179,229 sensors. On average, the users of isCGMS from Poland achieved lower estimated HbA1c, spent more time in range, and less time-above-range. The analyzed glucometrics improved as the scan rate frequency increased. The data also show that in real-life practice, a large number of patients may be willing to perform scanning more frequently than is usually assumed.
Journal: Revista Argentina de Endocrinología y Metabolismo
Summary: The goal of this work was to examine the usage of flash glucose monitoring in a developing country such as Argentina and its association with glycemic markers. Read More
App users experienced lower glucose variability, lower average glucose, less time in hyperglycemia, and greater time in range than reader users. The observed differences may be driven by the data sharing features inherent in the app. By sharing glucose data with one’s clinical team, healthcare professionals and patients may be able to make more informed treatment decisions.
2020
Journal: Diabetology & Metabolic Syndrome
Details: Cited by multiple articles
Summary: No previous studies had investigated the comparative effect of sensor-based monitoring on glycemic markers in developing countries like Brazil. Read More
The data comprised 688,640 readers and 7,329,052 sensors worldwide and included 17,691 readers and 147,166 sensors from Brazil. Similar to previous analyses, increased scan frequency was associated with better glycemic control – in this case, lower estimated HbA1c, lower time in hyperglycemia, and more time in range.
Journal: BMJ Open Diabetes Research & Care
Details: Cited by over 30 articles
Summary: In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings. Read More
Spanish users (n=22,949) collected 37.1 million glucose scans and checked glucose values via a mean of 13 scans/day. High scan rates were associated with the favorable glycemic markers of increased time-in-range and reduced time in hyperglycemia and hypoglycemia, and glucose variability
(La fréquence des scans du capteur de glucose FreeStyle Libre réalisés par le patient diabétique au quotidien est associée à de meilleurs paramètres de suivi de son profil glucosé : analyse de 312 millions d’heures de suivi en vraie vie en France)
Journal: Médecine des Maladies Métaboliques
Summary: This observational study evaluated the metabolic benefits as a function of the frequency of FreeStyle Libre scans. Read More
Data from 97,788 French patients from Sept 2014 - Sept 2018 were analyzed. When scan frequency was increased, estimated HbA1c was reduced, time in range was increased, and time in hypoglycemia was reduced. This study confirms that the frequency of FreeStyle Libre scans is associated with improved metabolic control, including time in range and time spent in hypoglycemia.
2019
Journal: BMJ Open Diabetes Research & Care
Details: Cited by over 15 articles
Summary: This analysis assessed the role of flash glucose monitoring in early and late changes in glycemic markers under real-life conditions. Read More
De-identified glucose results from 6,802 users with at least six months of data were analyzed after dividing into high, medium and low-risk groups based on time spent in hypoglycemia or hyperglycemia. The analysis determined that under real-world conditions, flash monitoring was associated with rapid and sustained reduction in dysglycemia with high-frequency scanners demonstrating more significant reduction in hyperglycemia.
2018
Journal: Diabetes Research and Clinical Practice
Details: Cited by over 150 articles
Summary: This was the first manuscript to analyze real-world data from FreeStyle Libre users to investigate the use of the system in real life clinical practice. Read More
Over 50,000 readers were included and over 90% of the data was from the seven initial FreeStyle Libre launch countries. Users performed an average of 16.3 glucose scans per day, almost four times more than average daily blood glucose checks previously reported. Higher scanning frequency was associated with better glycaemic measures including lower estimated HbA1c, decreased time in hyper and hypoglycemia and increased time in euglycemia with reduction in hypoglycemic exposure.
ADC-56426 Ver 1.0 06/22
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.
NO
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
NO